{
  "abstract": "Introduction Dalbavancin, a long-acting lipoglycopeptide, provides single-dose therapy equivalent to two weeks of oral antibiotics. While widely effective, its role in Emergency Medicine as a discharge enabler is less well described. We report our first-year experience, focusing on admission avoidance, patient characteristics, treatment pathways, and outcomes.Methods We conducted a retrospective cohort review of all patients treated with dalbavancin for cellulitis between July 2024 and June 2025. Data collected included demographics, cellulitis site, prior antibiotic exposure, microbiology, follow-up, and unscheduled returns.Results Thirty-seven patients were treated (median age 53 years, range 17–86; 83.8% male). The lower limb was the most frequent site (73.0%, n = 27), followed by upper limb (18.9%, n = 7), face (8.1%, n = 3), and neck (2.7%, n = 1). Dalbavancin was prescribed mainly in the Clinical Decision Unit (89.2%) rather than the Emergency Department (10.8%). Prior antibiotics were common: 62.2% (n = 23) received oral therapy (median 3 days, range 1–27), and 91.9% (n = 34) intravenous therapy. Microbiology was available in 18.9% (n = 7), most frequently isolating Staphylococcus aureus with one case of Pseudomonas aeruginosa. Follow-up was documented in 91.9% (n = 34): 78.4% (n = 29) attended once and 13.5% (n = 5) attended two or more reviews.Abstract #290 Table 1Patient characteristics and outcomes following Dalbavancin use Characteristic n (%) or Median [Range ] Total patients 37 Age, years 53 [17–86] Male 31 (83.8%) Infection site – lower limb 27 (73.0%) Infection site – upper limb 7 (18.9%) Infection site – face 3 (8.1%) Infection site – neck 1 (2.7%) Prior oral antibiotics 23 (62.2%), median 3 days [1–27] Prior IV antibiotics 34 (91.9%) Microbiology available 7 (18.9%) – mainly S. aureus, 1 Pseudomonas aeruginosa Unscheduled returns 5 (13.5%), no readmissions Documented follow-up 34 (91.9%) Conclusion Dalbavancin enabled safe discharge and admission avoidance in selected cellulitis patients with no readmissions and a low rate of unscheduled returns. Its frequent use after short intravenous courses highlights ongoing challenges in pathway adoption and clinician familiarity. These findings have prompted a quality improvement programme with pathway clarification, consultant re-education, and quarterly audit cycles, including KPIs for reduced CDU admissions. Dalbavancin has potential to become a cornerstone in emergency cellulitis management. *presenting author",
  "authors": [
    {
      "affiliations": [
        "ALERT, Emergency Department, University Hospital Limerick, Ireland"
      ],
      "name": "Muaz Elsamani"
    },
    {
      "affiliations": [
        "ALERT, Emergency Department, University Hospital Limerick, Ireland",
        "School of Medicine, University of Limerick"
      ],
      "name": "Caitriona Mullarkey"
    }
  ],
  "title": "#290 Dalbavancin use for cellulitis in emergency medicine – a one-year review",
  "uid": "22a2c775-9ecc-5d19-bd6e-2cdfb75f2b19"
}